Navigation Links
Human Genome Sciences Presents Results of Phase 2 Trial of Albuferon(R) in Chronic Hepatitis C Patients Who Failed To Respond To Previous Therapy
Date:11/5/2007

mcg and 1800 mcg. The most common adverse events were fatigue, headache, arthralgia (joint pain), myalgia (muscle pain), insomnia, nausea, cough, and pyrexia (fever). Discontinuation rates due to adverse events were: 4.2% for the 1200 mcg every four weeks group; 17.4% for the 900 mcg every two weeks group; 4.2% for the 1200 mcg every two weeks group; 9.1% for the 1500 mcg every two weeks group; and 18.2% for the 1800 mcg every two weeks group. Hematologic reductions stabilized by Week 8, were well managed with dose reductions, and returned to baseline following the completion of therapy.

"The results emerging from our Phase 2 program continue to support our belief that Albuferon could become an important therapeutic option for patients with chronic hepatitis C, including those that have failed prior therapy," said Mani Subramanian, M.D., Ph.D., Senior Director of Clinical Research, Infectious Diseases, HGS.

About Albuferon

Albuferon is a novel long-acting form of interferon alpha created by HGS using its proprietary albumin fusion technology. Albuferon results from the genetic fusion of human albumin and interferon alpha. Human albumin is the most prevalent naturally occurring blood protein in the human circulatory system, persisting in circulation in the body for more than 20 days. Research shows that genetic fusion of therapeutic proteins to human albumin decreases clearance and prolongs the half-life of the proteins. Recombinant interferon alpha is approved for the treatment of hepatitis C, hepatitis B and a number of cancers.

Albuferon is being developed by HGS and Novartis for the treatment of chronic hepatitis C under a worldwide co-development and commercialization agreement entered into in June 2006. HGS and Novartis will co-commercialize Albuferon in the United States and will share clinical development costs, U.S. commercialization costs and U.S. profits equally. Novartis will be responsible for commercialization in the rest of the
'/>"/>

SOURCE Human Genome Sciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Video: New Research Discovers Independent Brain Networks Control Human Walking
2. Lpath Demonstrates Strong Safety Profile of Lead Drug Candidate, Sphingomab(TM), in Non-Human Primates
3. Enrollment Begins on Human PK Study for Medidur(TM) FA
4. Human Genome Sciences Completes Enrollment of First Phase 3 Albuferon(R) Trial Ahead of Schedule
5. Study Confirms Limited Human-To-Human Spread of Avian-Flu Virus in Indonesia in 2006
6. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
7. Peregrine Researchers Report Data Showing Bavituximabs Potential to Shrink Human Prostate Tumors in Model of Relapsed Disease
8. Dr. Roger Kenneth Hershline PhD MD, CEO of Global Humanceuticals, Inc. Donates New HIV Drug
9. Study Shows Plasma-Derived Human Thrombin Equivalent to Bovine Thrombin in Achieving Hemostasis in Surgery
10. Tengion Launches Second Phase 2 Clinical Trial of Regenerated Human Organ
11. Flexible Medical Systems Raises $1.2M Seed Investment for Initial Human Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/30/2014)... --  NxStage® Kidney Care, Inc ., a subsidiary of NxStage® ... host the grand opening ceremony of its Oak ... Street on November 20, 2014 from 3pm – 7pm. The ... who are committed to providing patients with enhanced access to ... through more flexible dialysis treatment options.   The ...
(Date:10/30/2014)... Calif. , Oct. 30, 2014  Electronic ... dramatically as a result of government initiatives and ... - healthcare providers have invested over the past ... heart of health IT, and U.S. clinicians use ... Logo - http://photos.prnewswire.com/prnh/20141029/155278LOGO ...
(Date:10/30/2014)... 2014  Nektar Therapeutics (Nasdaq: NKTR ) ... ended September 30, 2014 on Thursday, November 6, 2014, ... Robin , president and chief executive officer, will host ... 5:00 p.m. Eastern Time (ET)/2:00 p.m. Pacific Time (PT). ... audio-only Webcast of the conference call can be accessed ...
Breaking Medicine Technology:Grand Opening of NxStage Kidney Care Oak Brook IL Center 2Grand Opening of NxStage Kidney Care Oak Brook IL Center 3Electronic Health Record Usability: CIOs Weigh In 2Electronic Health Record Usability: CIOs Weigh In 3Electronic Health Record Usability: CIOs Weigh In 4Nektar to Announce Financial Results for the Third Quarter 2014 on Thursday, November 6, 2014, After Close of U.S.-Based Financial Markets 2
(Date:10/30/2014)... 30, 2014 REV'D Provision Co. announced ... available through a unique service called, The Feed ... empower the everyday athlete. The Feed has taken the ... created a system to pass that information on to ... is now available on The Feed!” says REV’D® marketing ...
(Date:10/30/2014)... The Woodlands, TX (PRWEB) October 30, 2014 ... hospital system, released today its 2014 third quarter ... hospitals across Texas boasted infection rates of only ... also reported patient satisfaction scores exceeding 98 percent. ... this past quarter, which included rising satisfaction scores,” ...
(Date:10/30/2014)... (HealthDay News) -- Scientists who used stem cells to ... breakthrough could provide a new way to learn more ... The team used human pluripotent stem cells -- which ... -- to grow the functional miniature stomachs, to study ... cause of ulcers and stomach cancer. The miniature ...
(Date:10/30/2014)... -- Many U.S. colleges have indoor tanning salons ... the risk for skin cancer, researchers report. ... women, so colleges should adopt tanning-free policies, to ... "Public health efforts are needed to raise university ... that indoor tanning poses to young adults in ...
(Date:10/30/2014)... 2014 (HealthDay News) -- A new vaccine that could ... was approved by the U.S. Food and Drug Administration ... between the ages of 10 and 25 from invasive ... B bacteria. The bacteria can infect the bloodstream ... and brain. It is a leading cause of bacterial ...
Breaking Medicine News(10 mins):Health News:Nutrition Experts at TheFeed.com Get REV'D 2Health News:Nutrition Experts at TheFeed.com Get REV'D 3Health News:Victory Healthcare Releases Q3 Satisfaction, Infection Rates 2Health News:Victory Healthcare Releases Q3 Satisfaction, Infection Rates 3Health News:Many U.S. Colleges Have Indoor Tanning Salons On, Near Campus: Study 2Health News:FDA Approves New Vaccine to Protect Against Meningitis 2
... (ZixCorp(R)), (Nasdaq: ZIXI ), the leader in hosted ... corporate update by its chief executive officer, Rick Spurr. , ... ZixCorp and we are on target to report within the ... are that we should meet our revenue guidance of $7.3 ...
... 7 The National Inflation Association today released the following ... , "It is becoming increasingly likely that health care will ... There is no doubt about it that health care costs ... the government to do something about astronomical health care costs, ...
... , ,PROVIDENCE, R.I. [Brown University] Fueling the debate ... or repressed memory, Brown University political scientist Ross Cheit ... issue is how to prove whether the memories of ... and then resurface later in life. Cheit,s paper, co-authored ...
... Providence Service Corporation (Nasdaq: PRSC ) today commented ... state,s attempt to close its large budget deficit. ... our programs in California are primarily funded by Medicaid and ... do not expect to experience material funding issues for our ...
... study findings , TUESDAY, July 7 (HealthDay News) -- ... findings that show a reduced-dose schedule for the pneumococcal ... , The current recommended dose schedule for 7-valent pneumococcal ... the age of 6 months, followed by a booster ...
... less pain with conventional operation , TUESDAY, July 7 (HealthDay ... that can be caused by sciatica didn,t work as well ... expected treatment benefit of a faster rate of recovery from ... double-blind study," according to a report in the July 8 ...
Cached Medicine News:Health News:Zix Corporation CEO Provides Corporate Update for Second Quarter 2009 2Health News:Zix Corporation CEO Provides Corporate Update for Second Quarter 2009 3Health News:Zix Corporation CEO Provides Corporate Update for Second Quarter 2009 4Health News:NIA Says Health Care Will Cause U.S. Dollar Collapse 2Health News:NIA Says Health Care Will Cause U.S. Dollar Collapse 3Health News:Brown professor continues debate over recovered memory 2Health News:Providence Service Corporation Does Not Expect California Budget Issues to Materially Impact Its Business in the State 2Health News:Fewer Shots Could Still Protect Kids From Pneumonia 2Health News:Minimally Invasive Surgery Not Better for Sciatica 2Health News:Minimally Invasive Surgery Not Better for Sciatica 3
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: